In rare, previously unexplained cases, individual cancer patients respond to treatment much better than others do. Now, faster and cheaper DNA sequencing is allowing researchers to search the entire genetic material of such patients for the causes of their 'super responder' status. In one case, researchers linked one patient's exceptional response to Afinitor (everolimus) to a mutation in the TSC1 gene. They plan to develop a test for this mutation, hoping to identify other cancer patients who will respond strongly to Afinitor. Such studies may resurrect drug candidates that were abandoned after clinical trials, where they were ineffective in most, but very effective in a few patients. Clinical trials and clinics focusing specifically on super responders are being planned.